MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
SAN DIEGO, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Evofem, Inc. announces that Sandra Matsumoto has been named Vice President of Global Regulatory Affairs effective immediately. In this role, Dr. Matsumoto will be responsible for global regulatory strategy and lifecycle management of the Evofem product portfolio. She will report to Evofem Senior Vice President of Regulatory Affairs and Quality Assurance, Mary Jarosz.
"Sandra has extensive experience in the biotech and pharmaceutical industry," said Jarosz. "She has implemented global strategies from development to commercialization across several therapeutic areas and is a great addition to a well-established regulatory team."
Prior to joining Evofem, Dr. Matsumoto was the Senior Director of Global Regulatory Affairs for Vital Therapeutics, Inc., where she led biologics license application preparation for the treatment of severe liver disease. Before joining Vital, she held positions with increasing levels of responsibility in the areas of regulatory affairs, clinical development, and discovery research with several companies including Shire Regenerative Medicine and Illumina.
Dr. Matsumoto earned her PhD in Pharmacology and Toxicology from the University of Utah, her Master's of Science in Biology from California State University, Northridge and her Bachelor's of Science in Biology from UCLA. She also holds RAC certifications for the U.S. and E.U.
About Evofem
Evofem, Inc. is a late stage biotechnology company, headquartered in San Diego, CA, which focuses on the development and commercialization of women's reproductive health products, with a core focus on contraception.
Evofem, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem has two lead product candidates; Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
CONTACT: Media Inquiries
Ellen Thomas
+1.718.490.3248
[email protected]
